A Study to Evaluate MEDI5752 in Subjects with Advanced Solid Tumors

Study identifier:D7980C00001

ClinicalTrials.gov identifier:NCT03530397

EudraCT identifier:2018-003075-35

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects with Advanced Solid Tumors.

Medical condition

Selected advanced solid tumors

Phase

Phase 1

Healthy volunteers

No

Study drug

Pemetrexed, Carboplatin, Paclitaxel or Nab-Paclitaxel

Sex

All

Actual Enrollment

401

Study type

Interventional

Age

18 Years - 120 Years

Date

Study Start Date: 24 Apr 2018
Estimated Primary Completion Date: 30 Dec 2025
Estimated Study Completion Date: 30 Dec 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2024 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria